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ImagingAlzheimer's disease (AD) is the most common type of dementia. Both its incidence and prevalence are
expected to increase exponentially as populations' age worldwide. Despite impressive efforts of research
worldwide, neither cure nor effective preventive strategy is available for this devastating disease. Currently
there are several hypotheses onwhat causes AD, with the amyloid hypothesis being themost investigated and
accepted hypothesis over the past 20 years. However the exact role of amyloid-β in the onset and progression
of AD is not yet fully understood, and even the validity of the amyloid hypothesis itself is still being discussed.
This debate is fuelled by the vascular hypothesis, as increasing epidemiological, neuroimaging, pathological,
pharmacotherapeutic and clinical studies suggest that vascular pathology plays a key role in the onset and
progression of AD. We here will discuss arguments in favor and limitations of both hypotheses within the
framework of available literature, but also provide arguments for convergence of both hypotheses.
Finally we propose approaches that may aid in unraveling the etiology and treatment of AD. This article is part
of a Special Issue entitled: Imaging Brain Aging and Neurodegenerative disease.loid precursor protein; ApoE,
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Alzheimer's disease (AD) causes an immense economic burden and
an unparalleled social challenge with over 15 million persons affected
worldwide togetherwith a decreasing number of potential caregivers in
the comingdecades [1]. Before Alzheimer's publication on the disease in
1907, dementia had been recognized for centuries and was ever since
attributed to vascular factors as for example illustrated by Lobsteinwho
coined the term “dementia arteriosclerotica”, already as early as in1833.
And even before, the history of vascular dementia dates back to cases of
dementia after apoplexia described by Thomas Willis in 1672.
In 1906, it was Alzheimer, or actually his teacher Kraepelin, who
started confusion with the description of the case of 51-years oldAuguste D that resembled “ordinary dementia” cases but who was
considerably younger and had neuropsychiatric symptoms [2]. On
post mortem neuropathological examination her brain contained
senile plaques and neuroﬁbrillary tangles.
This presenile disorder affecting patients in their forties and ﬁfties
with early symptoms of a severe progressive dementia with focal
signs such as amnesia, aphasia, apraxia and agnosia was then named
AD. In his later work, Alzheimer reported the degeneration of the
smaller cerebral blood vessels at a cellular level in a 56 year-old
patient, a process also referred to as Alzheimer's sclerosis. Alzheimer
questioned whether the co-occurrence of plaques and tangles and
vascular pathology being typical or atypical for AD, an ever actual
issue.
After the identiﬁcation of the plaque's main compound amyloid in
the 1960's, much research was devoted on its physiology and
pathophysiology, followed by a reappraisal of vascular factors based
on the abundance of vascular changes in the brain of patients with
cognitive decline and dementia when large scale neuroimaging
became available [3–7].
Currently there are several hypotheses on what causes AD, with
the amyloid hypothesis being the most investigated and accepted
hypothesis over the past 20 years. However the exact role of
amyloid-β in the onset and progression of AD is not yet fully
understood, and even the validity of the amyloid hypothesis itself is
still being discussed. This debate is fuelled by the vascular hypothesis,
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cotherapeutic and clinical studies suggest that vascular pathology
plays a key role in the onset and progression of AD. We will give a
critical appraisal with respect to their causality in AD and provide a
framework that enables a convergence of the two hypotheses towards
one explanatory model for AD and that will provide clues for future
research.
2. The amyloid hypothesis
2.1. Observational
The ﬁrst description of the amyloid composition of the neuritic
plaques, that Alzheimer observed decades before, appeared in 1966 by
Roth, Tomlinson and Blessed. This British research group quantiﬁed the
relation between clinical symptoms and pathological changes (plaques
and tangles) in the brain [8,9]. In 1984 the amino-acid sequence of the
amyloid-beta peptidewas elucidated, that initiated the discussion on its
origin [10]. The presence of the amyloid-β protein was ﬁrst sequenced
from (especially leptomeningeal) blood vessels of AD patients and
patients with Down syndrome [11]. A year later the same peptide was
recognized as the primary component of the senile (neuritic) plaques of
AD patient brain tissue [12]. These ﬁndings resulted in the hypothesis
that the blood borne accumulation of amyloid resulted in plaques. The
subsequent cloning of the gene encoding for amyloid-β precursor
protein (APP) and its localization on chromosome 21 and that of
presenilin 1 and 2 that are nowknown to be involved in splicing theAPP
suggested that amyloid-β accumulation is the primary event in AD.
Mutations in the APP gene were identiﬁed causing hereditary cerebral
hemorrhage with amyloidosis (Dutch type), this showed that APP
mutations could cause amyloid-β deposition, outside the brain
parenchyma [13,14]. The amyloid-β protein is cleaved from APP by
the sequential action of β-secretase and γ-secretase respectively; the
resulting amyloid protein fragment can be either 40 (Aβ1–40) or 42
(Aβ1–42) amino acids in length. Mutations in the presenilins result in
relative high levels of extracellular Aβ42 [15]. Many mutations in these
genes have now been described, each with an early onset AD as clinical
picture, but it should be noted that these mutations represent less than
0.1% of all AD cases [16].Fig. 1. Interaction between the amyloid hypothesis and the vaApoliporotein E (apoE) is the most consistently associated risk
gene for AD, it is involved in the amyloid-β clearance and associated
with increased amyloid burden and cholinergic dysfunction. In-
dividuals with two apoE ε4 alleles have a more than seven times
increased risk of developing AD [17].
In the late 1980s and early 90s it was recognized that amyloid-β
protein was not only a pathological constituent but could also be part
of physiological cellular mechanisms throughout life of healthy
humans [18–20]. Based on these observations the later called
“amyloid hypothesis” of AD was formulated (left panel, Fig. 1)
[21,22]. In short, this theory implies that AD is initiated by abnormal
cleavage of the APP resulting in a chronically enhanced production
and/or decreased clearance of soluble, diffusible amyloid-β. This could
lead to a gradual precipitation of aggregated non-diffusible amyloid- β
in the form of spherical plaques and vascular deposits in AD. Factors
which cause this aggregated amyloid-β include genetic causes like
dominant mutations of the genes encoding APP and presenilin 1 and 2
[23,24].
In addition, tau, a microtubule-associated protein, is the major
constituent of neuroﬁbrillary tangles. The “amyloid hypothesis”
proposes that an imbalance between amyloid-β production and
amyloid-β clearance resulting in toxic concentrations of amyloid-β
which triggers changes in tau and consequent neuroﬁbrillary tangle
formation [25], although the pathways linking amyloid-β and tau are
not fully understood. Braak and Braak published the pathological
stages of distribution of neuroﬁbrillary tangles that followed a
predictable pattern, with initial changes in the entorhinal cortex,
than spread into the entorhinal region of the temporal cortex,
followed by involvement of the neocortical associated areas [26].
There is still conﬂicting evidence between the amyloid burden and
the attendant cognitive performance. In favor for a role of amyloid
pathology in cognitive impairment was the observation that neuro-
toxic amyloid-β soluble oligomers could impair cognitive function in
rats [27,28]. These highly organized, lowmolecular weight oligomeric
assemblies precede the formation of amyloid ﬁbrils and they have
been identiﬁed in the brains of patients suffering from AD as well [29].
From the viewpoint that amyloid-β is a crucial factor in the
etiology of AD it is evident that much effort has been put in its
detection during life; ideally within the living brain or, second best, inscular hypothesis in the etiology of Alzheimer's Disease.
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fairly reliable distinction between AD and non-demented can bemade
on the basis of CSF ﬁndings [30]. However, the results seem less
promising when other dementias, as in clinical practice, have to be
distinguished, necessitating further research on the role of amyloid-β
in the etiology, but also on its use as a diagnostic tool. Evidence from a
longitudinal study suggests that CSF biomarkers, amyloid-β(1–42),
tau and ptau-181, are not sensitive markers for disease progression in
Alzheimer's patients [17]. Although others do not agree with this
ﬁnding [31] and recent reports show a CSF AD proﬁle in subjects with
subjective andmild cognitive impairment [32] and a relation between
increased levels of t-tau and intensity of disease and disease
progression [33].
In-vivo detection of amyloid-β became possible with the devel-
opment of the Pittsburg Imaging Compound B (PIB) and recently also
other amyloid-probes that enable visualization of amyloid burden
using Positron Emission Tomography (PET) scanning [34]. Positive
cortical PiB binding has been associated with low cerebrospinal ﬂuid
Aβ42 concentrations in AD [35]. This development offers possibilities
for early diagnosis and possibly also tracking progression of disease,
although the latter could not be found in a recent small study, in
which it appears that anti-amyloid therapies will need to induce a
signiﬁcant decrease in amyloid-β load in order to detect a drug effect
with PIB PET [36]. As PiB is not ideal for commercialization, because of
its 20-minute half life, several 18F-labeled tracers have been
developed [37]. At this time, these tracers are undergoing extensive
phase II and III trials. Recently, it has been demonstrated that
ﬂorbetapir-PET imaging was correlated with the presence and density
of amyloid-β [38]. Next, to investigate the effect of novel amyloid-β
modifying drugs on a clinical level, these amyloid binding agents may
also have the potential to investigate the effects on the presence of
amyloid-β in both the parenchyma as vessel wall.
2.2. Experimental
The ultimate proof for a role of amyloid-β peptide in AD would be
to reduce the brain's amyloid-β burden, using disease modifying
therapies and to investigate its effect on cognitive decline. As such the
amyloid-β has become a major therapeutic target. Therapeutic
strategies include lowering the production of the peptide by 1)
prevention of APP transcription, 2) inhibiting the enzymes responsi-
ble for amyloid-β generation (APP splicing by β- and γ-secretase),
3) preventing aggregation of solid amyloid-β, and 4) increasing the
rate of amyloid-β clearance from the brain. Amyloid-β immunother-
apy uses anti amyloid-β antibodies, generated following vaccination
or introduced passively. Preclinical studies in animal models showed
that amyloid-β immunization lowered the plaque burden [39] and
reversed behavioral deﬁcits [40]. First phase human clinical trials in
AD in which patients were immunized with aggregated human
amyloid-β 1–42 to stimulate clearance of amyloid plaques were
associated with serious adverse events (meningoencephalitis), the
trial had to be terminated prematurely [41]. Later analysis of this
interrupted trial showed that some patients (“the antibody re-
sponders”) had an increased loss of brain volume and no better
cognitive performance compared to the placebo group, except for
some composite z-score of the neuropsychological test battery
[41,42]. On the basis of these studies numerous amyloid-β immuno-
therapies are currently in human clinical trials.
Another approach to decrease levels of amyloid-β is passive
immunization with antibodies targeting portions of the amyloid-β
molecule. Bapineuzumab is a humanized monoclonal antibody
investigated in two trials. In the ﬁrst trial the amyloid-β burden was
decreased, however in the other trial no difference was found in
cognitive function between the treatment group and the controls
[43,44]. A safety concern was the occurrence of reversible vasogenic
edema.Another area of drug development involves the targeting of γ
secretase, one of the enzymes required for production of amyloid-β
from APP. As γ-secretase has many functions in the body, treatment
with γ-secretase inhibitors may lead to toxicity. Nevertheless a
number of inhibitors have been tested. Recently, a large, multicentre,
randomized, double blind, placebo-controlled, phase III trial on
Tarenﬂurbil showed no beneﬁcial effect in the treatment group
compared to placebo [45].
In addition, although several observational studies have concluded
that the use of nonselective nonsteroidal anti-imﬂammatory drugs
(NSAIDs) is associated with a reduce risk of AD, [46] clinical trials of
nonselective or COX2-selective NSAIDs in patients with dementia or
with mild cognitive impairment have not demonstrated any effect on
cognitive performance [47–49].
Possible explanations for these negative trials may be because of
their use in patients with advanced stages of disease, the pathological
processes may start years before the onset of clinical symptoms, this
suggests that treatment administration would need to occur much
earlier in patients deemed to be at high risk. In addition, it might be
because of study design, sample size or choice of treatment dosage.
However, it may also be that the negative ﬁndings reﬂect the still
incomplete understanding of the pathogenesis of AD, and the role
other (neurodegenerative and vascular) factors.
2.3. Discrepancies
Notwithstanding the overwhelming observational data on amy-
loid and AD, some important issues need to be addressed.
First discrepancy is the negative results of the trials in which the
effect of amyloid-β lowering drugs on disease was studied. In
addition, pathological studies on the relation between senile plaques
and neuroﬁbrillary tangles (AD pathology) and cognitive performance
and clinical AD show various discrepancies. There are numerous
reports showing a lack between the degree of amyloid pathology and
cognitive function during life [50], whereas other studies correlated
soluble and ﬁbrillar forms of amyloid-β with cognitive scores [51,52].
Many cognitively intact, healthy elderly have abundant senile
plaques, some even with the same density of senile plaques as
patients with AD in their brains without clinical signs of AD [53,54].
Plaques and tangles are found in cognitive intact individuals after the
age of forty without neuronal loss [55]. This is in line with ﬁndings
from a large pathology study that found that there is much mixed
pathology (cerebrovascular and AD pathology) in healthy individuals
from the general population who did not meet the clinical diagnostic
criterium of dementia [56]. There are reports on several lines of
transgenic mice over expressing APP in which there is a correlation
between the extent of learning and memory deﬁcits and the amount
of deposited amyloid-β found in the central nervous system, [57]
however there are also reports on transgenic animalmodels with high
levels of brain amyloid deposits that show no signiﬁcant neurode-
generation [58]. A recent report shows that neuropathological
processes related to AD in persons without dementia were correlated
with subtle cognitive dysfunction and that by the age of 80–85 years
many non-demented elderly have substantial AD pathology [59].
Furthermore, recent studies in humans showed that clearance of
amyloid depositions resulted neither in cognitive improvement nor in
a decreased rate of mental deterioration. These observations suggests
that senile plaques may not be the main cause of neurodegeneration
and cognitive decline in AD, accordingly other theories have been
established over the past years.
The ﬁrst theory is based on soluble amyloid-β, which proposes that
toxic amyloid-β-42 or its oligomers interfere with synaptic plasticity
in vitro of with membrane dysfunction and promote cell death
[60,61]. However these ﬁndings are based on experimental animal's
models, over expressing exogenous APP, and may not be applicable to
AD. Soluble amyloid-β peptides however are normal components of
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conditions these peptides become toxic, especially as no signiﬁcant
disease-associated abnormalities have been detected with their
production [62].
The second theory is the presenilin hypothesis which suggests that
loss of function of presenilin may be the primary event triggering
neurodegeneration in AD. Amyloid-β-42 may act primarily to
antagonize presenilin dependent functions, possibly by operating as
active site-directed inhibitor of γ-secretase, mimicking the effect of
presenilin mutations. Loss of presenilin activity results in synaptic
dysfunction and ultimately leads to progressive neurodegeneration
characterized by loss of synapses, dendrites, and neurons, astrogliosis
and tau hyperphosphorylation [63].
Finally, others suggest that tau protein plays a central role in the
chain of events leading from amyloid neurotoxicity to tau hyperpho-
sphorylation, microtubular destabilization, disturbed axonal transport
and synaptic failure to neurodegeneration. In this hypothesis the
pathological conversion of normal tau into functionally impaired
phosphorylated tau, which forms neuroﬁbrillary tangles and dystro-
phic tau neuritis and thereby depleting levels of functional microtu-
bules binding and stabilization tau below a critical point that results in
depolymerization of microtubules and a disruption of axonal
transport. These events are thought to culminate in neuronal
dysfunction and degeneration, leading to AD [64].
Other mechanisms may also play a role, for example the cognitive
reserve theory [65]. The cognitive reserve theory provides at least two
explanations of not ﬁnding a relation between the degree of amyloid
pathology and cognition. The ﬁrst is that individuals functioning at a
previously high level possibly have a greater cognitive capacity and/or
more efﬁciency and in that way may be less susceptible to disruption
compared to the average elderly. Consequently, they may experience
a longer subclinical cognitive deterioration, despite the possible
presence of amyloid plaques. Another explanation could be the
presence of compensatory networks that may compensate for
amyloid-based disruption of pre-existing networks [26]. This may
obscure the relation between amyloid burden and the cognitive
decline during the course of AD.
3. Vascular hypothesis
3.1. Observational
The history of vascular dementia can be traced back to cases of
dementia postapoplexia described by Thomas Willis in 1672. In 1833
Lobstein introduced the term “dementia atherosclerotica”. In 1894
Binswanger described the subcortical arteriosclerotic encephalopa-
thy, now known as Binswanger disease. Before the CT andMRI era this
disease was thought to be very rare.
With the advent of non-invasive imaging of the brain with CT in
the 1970s and 1980s and MRI in the 90s it became evident that small
vessel disease was not rare at all and a common ﬁnding in the general
population and in AD patients. The term “leuko-araiosis” was
introduced only 25 years ago as a neutral term for deep white matter
changes on the basis of vascular disease that were considered to be
associated with cognitive impairment [66]. It was demonstrated that
“healthy” elderly with leuko-araiosis performed less on certain
cognitive tasks than those without leuko-araiosis and that, in patients
with AD, leuko-araiosis was associated with a greater degree of
cognitive impairment [67,68]. Large longitudinal population based
cohort studies were then initiated and consistently showed a relation
between several vascular risk factors and white matter lesions (WML)
[69–71]. These vascular risk factors, hypertension, diabetes, athero-
sclerosis, homocysteine, smoking and atrial ﬁbrillation have found to
be related to AD [72–76]. Presumably these relations underlie the
emergence of vascular (white matter) lesions, as it was demonstrated
that individuals with silent brain infracts, periventricular andsubcortical WML have an increased risk of AD [4]. Furthermore,
pathology studies have revealed the presence of ischemic lesions in
patients with AD and it was shown that among non-demented people
those with coronary heart disease had greater plaque burden in the
brain those without heart disease [77]. This resulted in large
population based autopsy studies to unravel the vascular risk factors
for cognitive decline in elderly. In a prospective population based
cohort study, 209 subjects consented to donate their brain for post-
mortem evaluation. Before, they all underwent neuropsychological
screening with incident dementia at 2 and 6 years as the primary
outcome measure [56]. The median age of death was 85 years; at that
time 48% of the subjects were demented of which 64% fulﬁlled the
criteria for probable or deﬁnite AD. Over one third of the clinically
diagnosed AD patients did not have any plaques at all whereas in one
third of the clinically non-demented elderly moderate to severe
plaques were found. Around 80% of the subjects had vascular
abnormalities of the brain, which were signiﬁcantly more severe in
the demented population. The vascular hypothesis emanated from
these ﬁndings (Fig. 1, right panel). Vascular risk factors induce
neurovascular dysfunction and cause endothelial damage by oxidative
stress and inﬂammation which lead to local hypoperfusion and
ischemia which are radiologically represented by WML and silent
and/or lacunar brain infarctions [78]. As discussed earlier, these
radiological changes are related to cognitive decline and dementia [4].
3.2. Experimental
Proof of concept for a role of vascular factors in the etiology of
dementia could come from intervention trials. In the Syst-Eur trial
showed that treatment of isolated systolic hypertension with calcium
antagonists among elderly over the age of 60 was associated with a
decrease of incident dementia. The absolute risk reduction was 3%
[79]. A 2-year open label extension of this study revealed the same
results; long-term antihypertensive therapy reduced the risk of
dementia by 55% compared with placebo (pb0.001) [80]. In the
Leiden 85-plus study it was also reported that the use of a calcium
antagonists prevents the development of dementia, they did not ﬁnd
this for other antihypertensive drugs. They suggested that the
protective effect found in the Syst-Eur trial and in their own study
was due to the effect of the calcium channel inhibition rather than its
blood pressure lowering properties [81]. The PROGRESS study was a
randomized, double blind, placebo controlled trial involving 6105
patients with previous stroke or ischemic attack. Participants were
assigned to active treatment (perindopril for all participants and
indapamine for those with neither an indication for nor a contrain-
dication to a diuretic) or matching placebo(s). After a follow-up of
3.9 years the risk of dementia was reduced from 7.1% to 6.3%
(nonsigniﬁcant) however the risk of cognitive decline was signiﬁ-
cantly reduced from 11% to 9.1%. Although, it could be that this beneﬁt
was due to the prevention of recurrent stroke [82]. Preliminary results
of the observational OSCAR study support these ﬁndings [83].
3.3. Discrepancies
The previously described intervention studies could not be
replicated in several other studies. In the SHEP (systolic hypertension
in elderly program) study over 2000 patients were enrolled for
treatment with chlortalidone or placebo. Neither the decline in
cognitive function nor the incidence of dementia was signiﬁcantly
different between both groups after the treatment period [84]. In the
PROSPER study 6000 individuals with pre-existing vascular disease or
raised risk of such disease were randomized to either pravastatin or
placebo and followed for a mean of 3.2 years; one of the secondary
outcomes was cognitive decline. There were no signiﬁcant differences
for both groups and several cognitive rating scales [85].
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controlled trials (Syst-Eur trial, Scope trial, SHEP trial and the HYVET
trial) [79,84,86,87] on the effects of blood pressure lowering in late-
life on the development of cognitive decline and dementia on patients
with hypertension without apparent prior cerebrovascular disease.
This Cochrane concluded that blood pressure lowering in late-life is
not indicated with the aim of prevention of cognitive decline or
dementia alone, as only the Syst-Eur trial reported a beneﬁt from
treatment but neither the SCOPE, SHEP nor HYVET showed a beneﬁt,
and when the trials were entered in a meta-analysis, no statistically
signiﬁcant effect was seen [88]. As suggested by the authors, primary
outcome measures of all trials was cardiovascular disease, cognitive
function and dementia were secondary end-points. Trials were
terminated once the primary end-points were shown, in that way
possible beneﬁcial effects on cognition later in the follow-up can be
missed.
One of the possible explanations for this unequivocal role of
(treatment of) hypertension could be that the deleterious effects of
vascular risk factors in general and hypertension speciﬁc already
occurs decades before either cardiovascular or cognitive symptoms
occur. By the time the risk factors result into disease, the damage is
not remediable anymore.4. Convergence of the amyloid hypothesis toward the
vascular hypothesis
The diagnosis AD is based on the DSM-IV-TR [89] and the NINCDS-
ADRDA criteria [90]. In these criteria, the presence of other systemic
or brain diseases that may account for the progressive memory loss
and other cognitive deﬁcits, is an exclusion criterion. The criteria for
vascular dementia (NINDS-AIREN) include decline from a previously
higher level of functioning and manifested by impairment of memory
and of two or more other cognitive domains, which also exclude
patients systemic or brain disorders (such as AD) that in themselves
could account for deﬁcits in memory and cognition [91]. According to
these criteria the presence of cerebrovascular disease in a demented
individual rules out AD and vice versa.
However, the pathological change characteristics of AD are
observed together with vascular pathology in more than 40% of
elderly demented individuals [92]. Several studies show a variety of
underlying neuropathology among clinically diagnosed “probable” AD
patients. This pathology includes both Braak and Braaks' criteria
fulﬁlling amyloid plaques and tau tangles but also vascular lesions
such as lacunar infarctions and WML. A study among 102 women
between 76 and 100 years showed that dementia prevalence was
highest among those who met the neuropathological criteria for AD
and had coexisting vascular pathology [93]. In the presence of
vascular pathology in the basal ganglia, thalamus and deep white
matter fewer neuropathologic lesions were needed to result in a
clinical diagnosis of AD than in those without coexisting vascular
pathology, indicating the possible interaction between these factors.
In contrast, among those who did not meet the neuropathological
criteria for AD, vascular lesions were onlyweakly associatedwith poor
cognitive function and dementia. The Honolulu Asia Aging Study, a
community based study in very old men, of which 29% were
demented antemortem, suggested that the burden of AD and vascular
lesions independently contribute to a clinical AD diagnosis, which is
compatible with the view of the additive effect that these two types of
lesions on cognitive impairment may have [94]. The combination/
interaction of cerebrovascular damage with damage to the brain
caused by amyloid-β may result in a lower cognitive threshold of
dementia than the two separately [93]. The simultaneous double hit
by amyloid-β and vascular damage might affect cognitive function
more than the sum of parts, their effects may even be synergistic
[95,96].These ﬁndings are more or less conﬁrmed by the MRC CFAS study
that showed an extensive overlap of intermediate Alzheimer type
pathology among demented and non-demented older people despite
equivalent degrees of vascular pathology [56].
In addition, hypoxia and ischemia resulting from vascular
insufﬁciency may interact with amyloid-β on a more basic pathofy-
siological level. They increase the transcription of APP and its cleavage
by β-secretase resulting in more amyloid-β production [97,98].
Furthermore vascular damage may promote amyloid-β accumulation
in the CSF by reducing the vascular clearance of this peptide [99,100].
And vascular amyloid-β is a potent vasocontrictor and impairs
fundamental mechanisms regulating cerebral circulation and in that
way may induce ischemia [101,102]. In that way the interaction
between the amyloid and vascular pathway enhances their patho-
genic effects and favor the formation of amyloid plaques and cerebral
amyloid angiopathy (CAA) [103]. Others Imaging of in vivo paren-
chymal and vascular amyloid-β, with PET-radiopharmaceuticals could
help in studying these potential self strengthening mechanisms [104].
Next to investigate the effect of novel amyloid-βmodifying drugs on a
clinical level, PIB-PET may also have the potential to investigate these
effects on the presence of amyloid-β.
Neuroimaging studies lend further support for an interaction
between amyloid-β features with vascular factors and vice versa. The
key radiological hallmark of typical AD is the medial temporal lobe
atrophy (MTA). The degree of atrophy was reported to be related to
the disease stage deﬁned by Braak and Braak [105,106] but a relation
between vascular (risk) factors and the severity of MTA has also been
observed [107,108]. Non-demented patients with diabetes have more
MTA on MRI than those without diabetes [109]. At the population
level there is a positive association between blood pressure and
medial temporal lobe atrophy meaning that increase in blood
pressure was related to more severe MTA [110]. Among patients
with AD a linear relation between systolic blood pressure and the
severity of MTA has been observed. WML could be a possible
intermediate in this relation as both population based studies and
studies among AD patients showed a relation betweenWML andMTA
[107,108]. A small prospective study showed that baseline WML was
associated with progression of MTA among 35 clinically deﬁned
“probable” AD patients. Stratiﬁcation on WML indeed revealed that
the relation between blood pressure and MTA only existed in AD
patients with WML [111]. In stroke patients it was shown that
patients with post-stroke reduced episodic memory function had
reduced medial temporal lobe functionality as demonstrated by fMRI
[112]. Other cardiovascular risk factors than hypertension have been
related to AD. Diabetes mellitus doubles the risk of AD corresponding
with an increase in microinfarcts and without a corresponding
increase in plaques and tangles [113]. Higher total cholesterol, LDL
concentrations and a history of diabetes is associated with faster
cognitive decline in AD [114]. Additionally, in studies on AD patients
the presence of atherosclerosis was related to an increased frequency
of neuritic plaques and neuroﬁbrillary tangles [115,116]. Further-
more, treatment of vascular risk factors in patients with AD is
associated with slower cognitive decline [117]. Conversely, there is
increasing evidence for a role of the amyloidmetabolism on presumed
cerebral vascular lesions and its effects on cerebral blood vessels.
Cerebral microbleeds might be a missing link between the amyloid
and vascular hypothesis. Cerebral microbleeds in the cortico-
subcortical regions might be a marker of CAA [118]. CAA is
characterized by of deposition of amyloid-β peptide within the
walls of the small and medium sized cerebral arteries [119], and is
associatedwith AD [120]. ApoE plays a crucial role in lipidmetabolism
and neuronal repair [121]. The apoE ε4 allele is not only associated
with cognitive impairment and dementia, but also with vascular risk
factors for WML [122]. ε4 homozygotes exhibit more extensive WML
than other genotypes [123]. It was hypothesized that the ε4 allele was
related to cognitive impairment because of the presence of WML.
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tension and apoE ε4 allele with regard to subcortical WML, and
relations between plasma amyloid-β levels and WML and lacunar
infarcts in people who carry an apoE ε4 allele [124,125]. However,
studies in demented populations and other population based studies
could not ﬁnd these relations [126,127]. The ε4 allele modulates the
severity of amyloid-β deposits in animal models [128] and in humans
[129], especially in patients with WML [130]. In a sample of autopsy
proven of AD patients apoE ε4 was associated with small vessel
arteriosclerosis, microinfarcts, neuritic senile plaque density and CAA
[131]. On the other hand cerebral microbleeds in the deep graymatter
and infratentorial regions are related to hypertensive vasculopathy
and might be a result of microangiopathy, such as arteriosclerosis or
ischemia [132].
In addition, experimental ﬁndings suggest cytotoxic effects of
amyloid-β on the vascular smoothmuscle cells, resulting in prolonged
and intensiﬁed endothelium dependent vasoconstriction that could
possibly result in hypoperfusion [101]. In a study, based within the
same Rotterdam Study, in-vivo support for these observations has
been obtained. High plasma levels of amyloid-β assessed 6.5 years
before transcranial Doppler investigations were related to impaired
CO2 enhanced transcranial Doppler assessed vasomotor reactivity
[133].
Next to this classical approach, novel developments, including
those from other areas, may help in elucidating the cause of AD. One of
these could be the systems approach to the networks of aging as
proposed byWest [134]. This approach emphasizes the multiplicative
effect that damage in network systems such as the vascular tree may
have on organ functions in general. In this way the cerebrovascular
damage, probably highly related to amyloid plaque depositions in the
vascular wall, may act in a synergistic way with the amyloid plaques,
leading a further compromised neuronal function. In addition this
theory makes use of the fundamental physiological properties of
different species as they age with molecular and cellular changes,
analyzing a system from both a top-down (a systemdecomposing into
parts), but also from a bottom-up approach.
5. Future perspectives
Most likely there is no single one-risk factor based explanatory
model for AD as more and more evidence suggests that it is not a
single cause disease entity, but a variety of causes, including
neurodegenerative (amyloid-β), vascular and probably more.
None of these risk factors alone is proven to be a necessary risk
factor (which means that the disease (AD) must always be preceded
by this risk factor) or sufﬁcient risk factor (i.e. the risk factor always
leads to the disease). Most likely the factors described here are
contributory risk factors (the risk factor is sometimes succeeded by
AD and the other way around). In addition to this interaction between
several of these factorsmay also play a role in the ﬁnal development of
the clinical syndrome of AD as we call it today (Fig. 1).
Dementia is very complex disease in the elderly with a large
heterogeneity in phenotype and genotype, with a heterogeneous life-
time exposure to a lot of different frequently interacting vascular,
amyloid and/or other damaging risk factors.
In future research more distinctive and reliable biomarkers might
play an important role, yet they are part of the revised research
criteria for AD, proposed to allow earlier and more speciﬁc AD
diagnosis [135].
Although some discrepancies as discussed earlier, CSF markers
may be a potentially promising approach for pathology in vivo, as they
can distinguish between AD and non-demented patients and it was
shown that subjects with subjective and mild cognitive impairment
have a AD CSF proﬁle, and this proﬁle was predictive of AD-type
dementia[30,32] are related to. If amyloid deposition plays an
important role in the etiology of AD, development of anti-amyloid-βtherapies, including amyloid-β immunotherapy, that reduce the
plaque burden or even prevent the development of amyloid plaques
is one of many future approaches to reduce the ever-growing
incidence of AD.
Imaging can be used as another biomarker. With the advance of
imaging techniques that are now available, repeated imaging with
thinner slices in combination with a valid automated lesion detection
tool could quantify the total lesion volume more precisely. Further-
more, as identical appearing WML on conventional MRI are actually
histopathologically heterogeneous, [136] it could be that only WML
with the highest loss of structural integrity are related to cognitive
impairment. It is also important that only a small portion of the white
matter (usually less than a few percent) is affected by WML. As
conventional MRI is not sensitive to early loss of microstructural
integrity in the normal appearing white matter, possible changes in
this largest part of the white matter cannot be assessed. The integrity
of the normal appearing white matter might be an important factor
for a better understanding of the relation between white matter
integrity and cognitive function and decline. These limitations of
conventional MRI can potentially be overcome with the use of novel
imaging techniques as Diffusion Tensor Imaging (DTI) which allows
the assessment of the microstructural integrity of the whole white
matter [137]. DTI may particularly be suited to detect subtle white
matters' structural abnormalities at even earlier moments in time
(at least before detection with conventional FLAIR imaging). And as
such these early signs of microstructural loss can be found before
actual disabling cognitive consequences may have occurred and as
such may aid in the selection of patients who may be at risk for future
development of “leuko-araiosis” and the possible attendant cognitive
decline. Even more stringent treatment of vascular risk factors may,
although unproven until now, possibly postpone future cognitive
deterioration. In future it could be possible to use these new imaging
techniques to visualize neural compensation networks. Therapeutic
strategies may then be developed that aim at stimulating the
formation of such networks.
Analogous to the amyloid theory much needs to be done to
establish a causal role for vascular factors in the etiology of dementia,
as most of the data are cross-sectional or of non-replicated
intervention studies. In future research on the etiology of AD and
the possible role vascular factors in this etiology, the phenotype of the
study population should critically be deﬁned. This phenotype should
be deﬁned by the clinical presentation, exposure to risk factors and
age of the study population. In etiologic research, the phenotype
should not be based on the absence or presence of biomarkers as these
are the etiologic factors you want to investigate and when part of the
diagnosis, obviously there will be a relation between the biomarker
and disease. It should be a very large study sample in order to be able
to deﬁne subgroups to investigate interactions between these groups.
In prognostic or intervention trials biomarkers can be used in the
deﬁnition of disease, although there should be consensus on the
deﬁnition of these biomarkers. For example, the presence of WML,
there can rated semi-quantitatively, by location, by volume estimation
or by automated or manually segmented total volume, and with or
without taking silent brain infarcts or lacunar infarcts into consider-
ation or by using new imaging techniques which assess the
microstructural integrity of the whole white matter. Dementia should
be among the endpoints in any cardiovascular intervention trial, with
an extended, open-label follow up to be able to detect incident
dementia occurrence after the primary vascular outcome events.
6. Conclusion
In 1907, Aloïs Alzheimer described a clinical syndrome, now
known as AD, characterized by progressive behavioral abnormalities
with prominent focal symptoms and an impaired memory in a
relatively young woman.
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much older than Auguste D and the clinical symptoms differ.
Alzheimer most likely described a presenile dementia based on
amyloid-β pathology without, or with only few concomitant
(vascular) risk factors. Although some clinical similarities between
Auguste D's dementia and the senile dementia exist, the latter is
probably being caused by accumulated cerebral damage caused by
life-time exposure to vascular, amyloid and/or damaging factors that
probably differs in terms of pathophysiology from Auguste D.
Vascular factors as a contributing cause to the development of AD
have come into play again, next to affecting the large arteries at the
skull's base as one thought in the 19th century, the small vessels
(arterioles) deep within the brain parenchyma also play a role. The
presence of small vessel cerebrovascular disease in AD is very
common; cerebrovascular disease and AD share the same risk factors,
coexisting cerebrovascular disease and AD results in more severe
cognitive impairment, either by direct damage of the neural pathway
or indirect by worsening the impact of AD pathology.
As hypothesized by others, this suggests that cerebrovascular
disease may be in the causal pathway for development of AD or
interacts synergistically with AD pathology [103,138].
Future studies on the etiology of AD should preferably start with
proper diagnostic research criteria in order to exactly deﬁne the
disease investigated instead of etiologic research onmerely a complex
of symptoms rather than a single disease entity. A well described
phenotype and large numbers of patients are important factors to
enable unraveling the complex interacting pathologies, best in
etiological studies in vivo using MRI, CSF markers and PET [135].
Once that has been accomplished studies on etiology should be large,
prospective and presumably already start during mid-life or even
before. Treatment of risk factors found by this approach should then
be further evaluated in intervention studies with dementia as a
primary end point. We should also keep an open eye towards
innovative approaches including those derived from systems biology,
a ﬁeld which focuses on complex interactions of biological systems,
[134] that may possibly speed up the quest for the etiology of AD.
Imaging and biomarkers have improved dramatically over the last
ten years. Identifying the individuals at risk before clinical onset of
symptoms, might help us the treat these individuals and to reduce the
ever growing incidence of AD.
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